Unique targeting of androgen‐dependent and ‐independent AR signaling in prostate cancer to overcome androgen resistance

The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6

(2019) Sharleen V. Menezes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.

(2019) Kyung Chan Park et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling

(2017) Sharleen V. Menezes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion

(2017) Anup Sharma et al.   Molecular Oncology

Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen–Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1)

(2017) Ruxing Xi et al.   MOLECULAR PHARMACOLOGY

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells

(2017) Yangyang Han et al.   Theranostics

Non-Genomic Actions of the Androgen Receptor in Prostate Cancer

(2017) Jacky K. Leung et al.   Frontiers in Endocrinology

The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms

(2016) Zhu-Ling Guo et al.   Journal of Hematology & Oncology

Downregulation of N-myc downstream regulated gene 1 caused by the methylation of CpG islands of NDRG1 promoter promotes proliferation and invasion of prostate cancer cells

(2015) YALIN LI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways

(2015) Zaklina Kovacevic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the “Triad of Death” in cancer by Di-2-pyridylketone thiosemicarbazones

(2015) Patric J. Jansson et al.   PHARMACOLOGICAL RESEARCH

Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation

(2014) Donald J. Vander Griend et al.   International Journal of Biological Sciences

Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells

(2013) K M Dixon et al.   BRITISH JOURNAL OF CANCER

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

(2013) Mark Sanford   DRUGS

Transcriptional activity of c-Jun is critical for the suppression of AR function

(2013) Chih-Chao Hsu et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways

(2012) Zaklina Kovacevic et al.   ANTIOXIDANTS & REDOX SIGNALING

The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)

(2012) Zhiqiang Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Development of proteasome inhibitors as research tools and cancer drugs

(2012) Alfred L. Goldberg   JOURNAL OF CELL BIOLOGY

Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo

(2012) David B. Lovejoy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions

(2012) Keith F. Decker et al.   NUCLEIC ACIDS RESEARCH

Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer

(2012) S Ha et al.   ONCOGENE

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer

(2011) R Mukherjee et al.   BRITISH JOURNAL OF CANCER

Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation

(2011) Zi Fang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer

(2011) Z. Kovacevic et al.   MOLECULAR PHARMACOLOGY

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

(2011) M. J. Evans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PSA regulates androgen receptor expression in prostate cancer cells

(2011) Parmita Saxena et al.   PROSTATE

Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: Implications for iron-related dopaminergic neuron degeneration

(2010) Zhi Dong Zhou et al.   FREE RADICAL BIOLOGY AND MEDICINE

Suppression of the androgen receptor function by quercetin through protein–protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells

(2010) Huiqing Yuan et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase II  in Breast Cancer Cells

(2009) V. A. Rao et al.   CANCER RESEARCH

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients

(2008) P McCall et al.   BRITISH JOURNAL OF CANCER